Linezolid as rescue treatment for left-sided infective endocarditis: An observational, retrospective, multicenter study

European Journal of Clinical Microbiology and Infectious Diseases

Volumn 31, Issue 10, 2012, Pages 2567-2574

  Lauridsen, T K ^a   Bruun, L E ^b   Rasmussen, R V ^c   Arpi, M ^b   Risum, N ^b   Moser, C ^a   Johansen, H K ^a   Bundgaard, H ^a   Hassager, C ^a   Bruun, N E ^b  

^a Mental Health Center Glostrup   (Denmark)

^b GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^c HVIDOVRE HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

AMPICILLIN; CEFUROXIME; CIPROFLOXACIN; DICLOXACILLIN; FUSIDIC ACID; GENTAMICIN; LINEZOLID; MEROPENEM; METRONIDAZOLE; MOXIFLOXACIN; NETILMICIN; PENICILLIN G; PIPERACILLIN PLUS TAZOBACTAM; RIFAMPICIN; VANCOMYCIN;

ADULT; ANEMIA; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL ENDOCARDITIS; BETA HEMOLYTIC STREPTOCOCCUS; COAGULASE NEGATIVE STAPHYLOCOCCUS; COHORT ANALYSIS; DENMARK; DRUG HYPERSENSITIVITY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; ENTEROCOCCUS; ENTEROCOCCUS DURANS; ENTEROCOCCUS FAECALIS; FEMALE; FOLLOW UP; GRAM POSITIVE BACTERIUM; HOSPITAL DISCHARGE; HUMAN; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; MORTALITY; NEPHROTOXICITY; NEUROPATHY; OBSERVATIONAL STUDY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS ORALIS; STREPTOCOCCUS SANGUINIS; SURVIVAL RATE; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; UNIVERSITY HOSPITAL;

ACETAMIDES; AGED; ANTI-BACTERIAL AGENTS; DENMARK; DRUG TOLERANCE; ENDOCARDITIS, BACTERIAL; ENTEROCOCCUS; FEMALE; FOLLOW-UP STUDIES; HOSPITAL MORTALITY; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; OXAZOLIDINONES; RETROSPECTIVE STUDIES; STREPTOCOCCUS; SURVIVAL ANALYSIS; TERTIARY CARE CENTERS; TREATMENT OUTCOME;

EID: 84869098294     PISSN: 09349723     EISSN: 14354373     Source Type: Journal    
DOI: 10.1007/s10096-012-1597-7     Document Type: Article

References (24)

1. Moellering RC (2003) Linezolid: the first oxazolidinone antimicrobial. Ann Intern Med 138:135-142
2. Rubinstein E, Isturiz R, Standiford HC et al (2003) Worldwide assessment of linezolid's clinical safety and tolerability: comparatorcontrolled phase III studies. Antimicrob Agents Chemother 47:1824-1831
3. Vinh DC, Rubinstein E (2009) Linezolid: a review of safety and tolerability. J Infect 59:S59-S74
4. Oramas-Shirey MP, Buchanan LV, Dileto-Fang CL et al (2001) Efficacy of linezolid in a staphylococcal endocarditis rabbit model. J Antimicrob Chemother 47:349-352
5. Patel R, Rouse MS, Piper KE et al (2001) Linezolid therapy of vancomycin-resistant Enterococcus faecium experimental endocarditis. Antimicrob Agents Chemother 45:621-623
6. Tsaganos T, Skiadas I, Koutoukas P et al (2008) Efficacy and pharmacodynamics of linezolid, alone and in combination with rifampicin, in an experimental model of methicillin-resistant Staphylococcus aureus endocarditis. J Antimicrob Chemother 62 (2):381-383
7. Mancino P, Ucciferri C, Falasca K et al (2008) Methicillin-resistant Staphylococcus epidermidis (MRSE) endocarditis treated with linezolid. Scand J Infect Dis 40:67-73
8. Muñoz P, Rodríguez-Creixéms M, Moreno M et al (2007) Linezolid therapy for infective endocarditis. Clin Microbiol Infect 13:211-215
9. Lauridsen TK, Arpi M, Bruun NE (2010) Linezolid therapy for infectious endocarditis. Ugeskr Laeger 172(16):1215-1216
10. Buchholtz K, Larsen CT, Hassager C et al (2009) Severity of gentamicin's nephrotoxic effect on patients with infective endocarditis: a prospective observational cohort study of 373 patients. Clin Infect Dis 48(1):65-71
11. Durack DT, Lukes AS, Bright DK (1994) New criteria for diagnosis of infective endocarditis: utilization of specific echocardiographic findings. Duke Endocarditis service. Am J Med 96(3):200-209
12. Li JS, Sexton DJ, Mick N et al (2000) Proposed modifications to the Duke criteria for the diagnosis of infective endocarditis. Clin Infect Dis 30(4):633-638
13. National Committee for Clinical Laboratory Standards (NCCLS) (2000) Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically-fifth edition: approved standard M7-A5. NCCLS, Wayne, PA
14. National Committee for Clinical Laboratory Standards (NCCLS) (2000) Performance standards for antimicrobial susceptibility testing-Tenth informational supplement, M100-S10. NCCLS, Wayne, PA
15. Noskin GA, Siddiqui F, Stosor V et al (1999) In vitro activities of linezolid against important Gram-positive bacterial pathogens including vancomycin-resistant enterococci. Antimicrob Agents Chemother 43(8):2059-2062
16. Zaoutis T, Moore LS, Furness K et al (2001) In vitro activities of linezolid, meropenem, and quinupristin-dalfopristin against Group C and G streptococci, including vancomycin-Tolerant isolates. Antimicrob Agents Chemother 45(7):1952-1954
17. Fuchs PC, Barry AL, Brown SD (2002) In vitro bactericidal activity of daptomycin against staphylococci. J Antimicrob Chemother 49:467-470
18. Habib G, Hoen B, Tornos P et al ESC Committee for Practice Guidelines (2009) Guidelines on the prevention, diagnosis, and treatment of infective endocarditis (new version 2009): the Task Force on the Prevention, Diagnosis, and Treatment of Infective Endocarditis of the European Society of Cardiology (ESC). Endorsed by the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) and the International Society of Chemotherapy (ISC) for Infection and Cancer. Eur Heart J 19:2369-2413
19. Bruun NE, Egeblad H, Elming H, Fuursted K, Hassager C, Helweg-Larsen J, et al. NBV 2011, http://www.cardio.dk/nbv/infektios-endocarditis
20. World Health Organization (WHO) (2003) WHO toxicity grading scale for determining the severity of adverse events. Available online at: http://www.icssc.org/Documents/Resources/AEManual2003AppendicesFebruary-06- 2003%20final.pdf
21. Vardakas KZ, Kioumis I, Falagas ME (2009) Association of pharmacokinetic and pharmacodynamic aspects of linezolid with infection outcome. Curr Drug Metab 10:2-12
22. Gould FK (2011) Linezolid: safety and efficacy in special populations. J Antimicrob Chemother 66(Suppl 4):iv3-iv6
23. Bressler AM, Zimmer SM, Gilmore JL et al (2004) Peripheral neuropathy associated with prolonged use of linezolid. Lancet Infect Dis 4:528-531
24. Brown J, Aitken SL, van Manen RP (2011) Potential for linezolidrelated blindness: a review of spontaneous adverse event reports. Pharmacotherapy 31(6):585-590